Aastrom Biosciences Inc. (Nasdaq: ASTM) will end development of its critical limb ischemia treatment. The stock price plunged 44 cents to $0.71.
Aastrom Biosciences Ends Clinical Study
March 27, 2013 at 12:31 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.